NCT03288493: Phase 1/2 - P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Myeloma
Updated: Jun 15, 2022
(PRIME)
NCT03288493: Phase 1/2 - P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
NCT03288493: Phase 1/2 - P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
Phase 1 of the study is comprised of an open-label, single ascending dose (SAD), multiple cohort study; a multiple dose cycle administration cohort study; and a combination administration study of P-BCMA-101 autologous T stem cell memory (Tscm) CAR-T cells in patients with relapsed / refractory MM. Followed by a Phase 2, open-label, efficacy and safety study. Rimiducid may be administered as indicated.
Sponsor
Collaborator
California Institute for Regenerative Medicine (CIRM)
ClinicalTrials.gov Identifier: NCT03288493
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P BCMA-101 in Subjects With Relapsed / Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME)
First Posted : September 20, 2017
Click here for details on Clinicaltrials.gov
Biological: P-BCMA-101 CAR-T cells
autologous anti-BCMA centyrin-based chimeric antigen receptor-expressing Tscm
autologous P-BCMA-101 CAR-T cells
autologous P-BCMA-101 CARTyrin-T cells
Drug: Rimiducid
134 Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies
Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: CAR T Therapies for Myeloma: Novel Approaches and Longer-Term Follow Up Data
Hematology Disease Topics & Pathways:
Biological, Therapies, CAR-Ts
Saturday, December 5, 2020: 10:45 AM
- California: University of California San Diego
- California: University of California San Francisco
- Colorado: Sarah Cannon/Colorado Blood Cancer Institute Denver
- Illinois: University of Chicago
- Maryland: Johns Hopkins Baltimore
- New Jersey: Hackensack University Medical Center
- Pennsylvania: University of Pennsylvania Philadelphia
- Tennessee: Sarah Cannon Research Institute Nashville
- Texas: The University of Texas MD Anderson Cancer Center Houston
- Washington: Swedish Cancer Inst Seattle
Locations
United States, Arizona
United States, California
United States, Colorado
United States, Illinois
United States, Kansas
United States, Maryland
United States, Michigan
United States, New Jersey
United States, Pennsylvania
United States, Tennessee
United States, Texas
United States, Washington